Background
Phase III clinical trials comparing a standard treatment to a new therapy are
often monitored for futility, that is, convincing evidence that the outcome of the
new treatment is not as good as that specified by the alternative hypothesis.
Fleming, Harrington, and O’Brien (FHOB) proposed a popular futility monitoring
method, based upon repeated testing of the alternative hypothesis at some fixed
p-value (often set at p = 0.005).
Purpose
To demonstrate several interesting properties of the boundary, and to suggest
alternative boundaries on the null hypothesis normalized test statistic, which cross
zero at 50% of the expected total information.
Methods
The FHOB boundary is redefined as a boundary on the null hypothesis
normalized test statistic and re-parameterized.
Results
FHOB-type boundaries are shown to be a function only of the significance
level and power of the primary test of hypothesis, and the p-value
used for repeated testing of the alternative hypothesis. The boundary can be
‘centered’ (in the sense of crossing zero) at some fixed percentage of the expected
total information and the rate at which the boundary increases is related to the
significance level and power of the primary test of hypothesis.
Limitations
Other futility monitoring boundaries exist and have differing operating
characteristics.
Conclusions
The standard FHOB boundary, based upon repeated testing of the alternative
hypothesis at p = 0.005 may be considered unnecessarily conservative
in some settings and a monitoring boundary is proposed that is more likely to lead to
a recommendation of futility when the null hypothesis is true.